RNS Announcements

All the posts published.

General Counsel Strategic Hire and Grant of Options

May 19, 2022
-
News, RNS Announcements
NetScientific plc (“NetScientific” or the “Company”) General Counsel Strategic Hire and Grant of Options   NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation group, is delighted to announce the appointment of its first General Counsel, Ed Hooper, with immediate effect. Ed also joins as Group Company Secretary and as Executive Director to the Company's corporate finance specialist subsidiary,…

ProAxsis announces “impressive” results in performance evaluation of the in-licensed AstraZeneca COVID-19 antibody test

May 16, 2022
-
News, RNS Announcements
NetScientific plc (“NetScientific”, the “Group” or the “Company”) ProAxsis Update   ProAxsis announces “impressive” results in performance evaluation of the in-licensed AstraZeneca COVID-19 antibody test   Successful completion of evaluation of the AstraZeneca COVID-19 antibody test The assay showed exceptional levels of sensitivity and specificity of 100% and 99.3% respectively Successful development strengthens ProAxsis’s expanding product range and international customer offering Additive to NetScientific’s…

Preliminary Results for the year ended 31 December 2021

May 12, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific", “NSCI”, the Group” or the "Company") Preliminary Results for the year ended 31 December 2021   Good results demonstrate excellent progress in growth strategy to realise shareholder returns   NetScientific plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces its preliminary results for the year ended 31 December 2021.   This was an excellent year…

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

May 11, 2022
-
News, RNS Announcements
11th May 2022 NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today provided a business update and first-quarter financial results for the year ended December 31, 2022.…

Notice of Results

May 9, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific", the "Group" or the "Company") Notice of Results Investor Presentation NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, will announce results for the year ended 31 December 2021 on Thursday 12 May.   Analyst Briefing: 09.30, Thursday 12 May Management will be hosting a remote presentation via web conference on the day of the…

NetScientific acquires of 30% of Vortex Biotech Holdings

May 6, 2022
-
News, RNS Announcements
NetScientific plc (“NetScientific”, the “Group” or the “Company”) Acquisition of 30% of Vortex Biotech Holdings   NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group announces the conditional acquisition of a 30 per cent. stake in Vortex Biotech Holdings Ltd (“VBHL”) (the “Acquisition”). The Acquisition is conditional upon the receipt by Deeptech Disruptive Growth Investments Ltd (“Deeptech”) of…

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

Mar 31, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific" or the "Group") PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results London, UK – 31 March 2022 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today provided a business update and announced its financial results for the year ended December…

NetScientific Q1 2022 Newsletter

Mar 4, 2022
-
News, RNS Announcements
NetScientific Q1 2022 Newsletter (Click to view full Newsletter)   Dear NetScientific PLC Shareholders and Stakeholders, In advance of the annual report which will be published at the beginning of April, we would like to provide you with a brief update. Management remains confident in the Company’s long-term prospects despite the ongoing broader market challenges. The last few months have seen significant turmoil in…

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With Merck’s anti PD-therapy KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Feb 24, 2022
-
News, RNS Announcements
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With Merck’s anti PD-therapy KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium   Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and…

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

Feb 15, 2022
-
News, RNS Announcements
 NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Clinical Trial with Mayo Clinic   PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer   The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer   London, UK – 15 February 2022 - NetScientific plc (AIM: NSCI), the international life sciences…
RNS Announcements Archives - NetScientific